Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK earnings

This article was originally published in The Tan Sheet

Executive Summary

Consumer Healthcare sales grew 2% in 2005 to reach $5.46 bil. for the year, GlaxoSmithKline announces Feb. 8. OTC drug sales were up 1% to $2.4 bil. (£ = $1.74), with growth in analgesics up 5% and respiratory tract drugs up 6%. The consumer division's September sale of five U.S. prescription dermatologicals contributed to a 12% drop in sales for the unit. The firm is "absolutely confident" that its Consumer division can continue to increase operating margins, CEO J.P. Garnier stated during an earnings call. The comment was a response to a question about whether the division's operating margins, which have increased from 20% to 24% in recent years, are sustainable. "I think what's going to affect margin is the overall revenue growth of the consumer business in '06," Garnier stated. "But we do have a number of programs where actually we convert cost saving from manufacturing and SG&A into more promotion because promotion drives the sales line in this business." The firm is awaiting an FDA decision on the proposed OTC sale of Alli (orlistat 60 mg)...

You may also be interested in...



Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel